{"type":"trials","record":{"id":42308,"source_id":"clinicaltrials-gov","external_id":"NCT04270669","title":"Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration","brief_summary":"This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple administration.","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"RemeGen Co., Ltd.","enrollment":37,"countries":["China"],"start_date":"2020-04-15","completion_date":"2021-10-29","last_update_date":"2022-01-10","source_url":"https://clinicaltrials.gov/study/NCT04270669","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 80 Years","comparator":null,"organization":"RemeGen Co., Ltd.","interventions":["intravitreal injection of RC28-E 0.5mg","intravitreal injection of RC28-E 1.0mg","intravitreal injection of RC28-E2.0mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change of BCVA from baseline at 12 week; — Baseline, Week 12","Mean change of BCVA from baseline at 48 week; — Baseline, Week 48","Incidence and severity of AEs — Baseline up to Week 48","The pharmacokinetic (PK) characteristics of RC28-E; — Baseline up to Week 48","Frequency of administration RC28-E within 48 weeks; — Baseline up to Week 48","Mean change of BCVA from baseline at Protocol Specified Time-Points. — Baseline up to Week 48"],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Wet Age-Related Macular Degeneration","intravitreal injection of RC28-E 0.5mg","intravitreal injection of RC28-E 1.0mg","intravitreal injection of RC28-E2.0mg"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04270669","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-04-15 to 2021-10-29","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.949Z","intervention":["intravitreal injection of RC28-E 0.5mg","intravitreal injection of RC28-E 1.0mg","intravitreal injection of RC28-E2.0mg"],"participants":37,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change of BCVA from baseline at 12 week; — Baseline, Week 12","Mean change of BCVA from baseline at 48 week; — Baseline, Week 48","Incidence and severity of AEs — Baseline up to Week 48","The pharmacokinetic (PK) characteristics of RC28-E; — Baseline up to Week 48","Frequency of administration RC28-E within 48 weeks; — Baseline up to Week 48","Mean change of BCVA from baseline at Protocol Specified Time-Points. — Baseline up to Week 48"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42308","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}